Publication:
Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke.

Loading...
Thumbnail Image

Date

2021-02-10

Authors

Ramiro, Laura
Abraira, Laura
Quintana, Manuel
Garcia-Rodriguez, Paula
Santamarina, Estevo
alvarez-Sabin, Jose
Zaragoza, Josep
Hernandez-Perez, Maria
Ustrell, Xavier
Lara, Blanca

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI AG
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z-scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin > quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007-0.048), p quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007-0.048), p quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007-0.048), p quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007-0.048), p quartile 3 was an independent predictor of mortality due to stroke. Altogether, endostatin, TNF-R1, and IL-6 circulating levels may aid in long-term mortality prediction after stroke.

Description

MeSH Terms

Ischemic Stroke
Receptors, Tumor Necrosis Factor, Type I
Endostatins
Interleukin-6
Follow-Up Studies
Stroke
Immunoassay
Multivariate Analysis
Hospitals

DeCS Terms

Biomarcadores
Mortalidad
Interleucinas
Endostatinas
Accidente cerebrovascular isquémico
Inseminación artificial heteróloga
Interleucina-6
Hipertensión
Inmunoensayo
Análisis multivariante

CIE Terms

Keywords

IL-6, TNF-R1, biomarker, endostatin, ischemic stroke, mortality

Citation

Ramiro L, Abraira L, Quintana M, García-Rodríguez P, Santamarina E, Álvarez-Sabín J, et al. Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke. Life (Basel). 2021 Feb 10;11(2):135.